Athira Pharma (NASDAQ:LONA) CEO Mark James Litton Sells 5,156 Shares

Athira Pharma, Inc. (NASDAQ:LONA) CEO Mark James Litton sold 5,156 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total value of $27,687.72. Following the sale, the chief executive officer owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. This represents a 8.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Athira Pharma Price Performance

Shares of Athira Pharma stock traded down $0.61 during trading on Thursday, reaching $5.37. The company’s stock had a trading volume of 121,497 shares, compared to its average volume of 52,719. Athira Pharma, Inc. has a 1-year low of $2.20 and a 1-year high of $8.36.

Analyst Ratings Changes

Several brokerages recently commented on LONA. Cantor Fitzgerald assumed coverage on shares of Athira Pharma in a research report on Thursday, February 26th. They issued an “overweight” rating for the company. Zacks Research raised shares of Athira Pharma to a “hold” rating in a report on Friday, February 27th. Weiss Ratings began coverage on shares of Athira Pharma in a report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Wall Street Zen downgraded Athira Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Thursday, February 19th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.